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Background
More than 30% of patients with pleural infection either 
die or require surgery. Drainage of infected ﬂ uid is the 
key to successful treatment, but intrapleural ﬁ brinolytic 
therapy did not improve outcomes in an earlier, large, 
randomized trial therapy (Multicenter Intrapleural Sepsis 
Trial [MIST1]).
Methods
Objective: To evaluate the eﬃ  cacy and safety of intra-
pleural DNase alone, alteplase alone, or the combination 
of both, to improve pleural drainage.
Design: Multicenter, double-blind, double-dummy, 2x2 
factorial randomized trial.
Setting: Eleven centers in the United Kingdom (UK).
Subjects: Adult patients (mean age 59  years, 72% men), 
who had clinical evidence of infection, and pleural ﬂ uid 
that had macroscopic purulence, a positive culture or 
Gram stain for bacteria, or a pH < 7.2.
Intervention: Patients were assigned to 1 of the 4 study 
inter ventions for 3 days: double placebo, intrapleural 
tissue plasminogen activator (t-PA) and DNase, t-PA and 
placebo, or DNase and placebo.
Outcomes: Th e primary outcome was the change in pleural 
opacity, measured as the percentage of the hemithorax 
occupied by eﬀ usion, on chest radiography on day  7 as 
compared with day  1. Secondary outcomes included 
referral for surgery, duration of hospital stay, and adverse 
events.
Results
Th e mean (±SD) change in pleural opacity was greater in 
the t-PA–DNase group than in the placebo group 
(−29.5 ± 23.3% vs. −17.2 ± 19.6%; diﬀ erence, −7.9%; 95% 
conﬁ dence interval [CI], −13.4 to −2.4; P  =  0.005). Th e 
change observed with t-PA alone and with DNase alone 
(−17.2  ±  24.3 and −14.7  ±  16.4%, respectively) was not 
signiﬁ cantly diﬀ erent from that observed with placebo. 
Th e frequency of surgical referral at 3 months was lower 
in the t-PA–DNase group than in the placebo group (2 of 
48 patients [4%] vs. 8 of 51 patients [16%]; odds ratio for 
surgical referral, 0.17; 95% CI, 0.03 to 0.87; P = 0.03) but 
was greater in the DNase group (18 of 46 patients [39%]) 
than in the placebo group (odds ratio, 3.56; 95% CI, 1.30 
to 9.75; P  =  0.01). Combined t-PA–DNase therapy was 
associated with a reduction in the hospital stay, as 
compared with placebo (diﬀ erence, −6.7  days; 95% CI, 
−12.0 to −1.9; P = 0.006). Hospital stay with either agent 
alone was not signiﬁ cantly diﬀ erent from that with 
placebo. Th e frequency of adverse events did not diﬀ er 
signiﬁ cantly among the groups.
Conclusions
Intrapleural t-PA–DNase therapy improved ﬂ uid drain-
age in patients with pleural infection and reduced the 
frequency of surgical referral and the duration of hospital 
stay. Treatment with DNase alone or t-PA alone was 
ineﬀ ective.
Commentary
More than 65,000 cases of pleural infection occur in the 
United States and United Kingdom each year [1], and the 
incidence is increasing in both children and adults [2]. 
Both community and hospital acquired bacterial 
pneumonia are complicated by pleural infections [3]. 
Despite the advances in therapeutic strategies, pleural 
infections are associated with high mortality rates of 
10-20% [4].© 2010 BioMed Central Ltd
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Th ere are several classiﬁ cations of pleural eﬀ usions 
based on evolution (exudative, ﬁ brinoproliferative with 
evidence of loculation, and formation of ﬁ brous peel) and 
ﬂ uid characteristics (clear, viscous, or pus). Drainage 
alone is usually adequate for an uncomplicated eﬀ usion. 
However, drainage is often insuﬃ  cient for patients with 
pleural infection who have a complicated eﬀ usion with 
increased viscosity and loculation [5]. Th e standard 
management of pleural infections consists of antibiotics 
and draining the infected pleural ﬂ uid [6]. However, more 
than 30% of patients fail standard therapy and require 
surgical referral. Th ese patients incur a longer duration of 
hospital stay of 12-15  days and increased utilization of 
healthcare resources [4].
Observational data suggest that using ﬁ brinolytic drugs 
in the intrapleural space can decrease the failure rate, 
reduce surgical referral, and improve chest tube drainage 
by cleaving intrapleural ﬁ brinous septations [7,8]. Th is 
theory was tested by many randomized controlled trials 
using diﬀ erent ﬁ brinolytics, but failed to improve 
clinically meaningful end points [9]. Most notably, the 
454 patients in the Multicenter Intrapleural Sepsis Trial 
(MIST1) showed no beneﬁ t from intrapleural strepto-
kinase. However, the absence of beneﬁ t was felt possibly 
due to the presence of free extracellular deoxyribonucleic 
acid (DNA) and other bacterial components in the 
pleural space, which increase ﬂ uid viscosity and hinder 
ﬁ brinolysis [8]. Adding DNase to cleave the free DNA 
may reduce ﬂ uid viscosity and permit pleural clearance 
by ﬁ brinolytic drugs [10].
To test this hypothesis, the second multicenter trial 
(MIST2) by Rahman and colleagues was conducted at 11 
centers in the UK. In this randomized trial, the authors 
used a diﬀ erent intrapleural ﬁ brinolytic agent (t-PA 
rather than streptokinase) and added DNase for cleavage 
of free DNA. Th e authors conducted a standard factorial 
study analysis and found a signiﬁ cant interaction between 
t-PA and DNase with regard to the primary outcome. 
Th ey therefore compared each of the three intervention 
groups to placebo.
Th e t-PA-DNase combination was signiﬁ cantly superior 
to placebo and each drug alone in improving the changes 
in opacity on chest x-ray on day 7 vs. day 1 (primary end 
point), decreasing the number of surgical referrals at 3 and 
12  months (4% vs. 14%), and decreasing the days of 
hospitalizations by 6.7 days. However, monotherapy with 
either t-PA or DNase showed no beneﬁ t when compared 
to placebo, and DNase alone resulted in an increase in 
surgical referrals and hospitalization days compared to 
placebo.
Strengths of this trial include: a well-deﬁ ned study 
protocol, multicenter, randomized, double-blind, double-
dummy design, and complete follow-up. Th ere are a few 
limitations. First, although only 3 serious adverse events 
with pulmonary bleeding (intrapleural hemorrhage, 
hemoptysis) occurred, all three were in the t-PA-DNase 
group (n = 52). Future use of this drug combination should 
carefully monitor for pulmonary bleeding. Second, the 
primary end point was the absolute change in chest x-ray 
opacity. However, the trial was powered to detect a 
slightly diﬀ erent endpoint, the proportion of patients 
who had a 50% relative reduction in opacity. Never-
theless, the overall results were striking, with only one 
patient in the t-PA-DNase arm not achieving any opaci-
ﬁ cation reduction, compared to several patients in the 
other arms. Additionally, there was reduction in the 
number of surgical referrals, a patient-centered endpoint.
Recommendation
Rahman and colleagues should be commended for 
demonstrating that dual intrapleural therapy with t-PA 
and DNase in patients with pleural infection improved 
changes in opacity on chest x-ray and reduced need for 
surgical intervention and hospital stay. Although larger 
trials are needed to replicate these results, dual 
intrapleural therapy may be a useful option, especially for 
patients who are high-risk for surgery.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA. 
2The Clinical Research, Investigation, and Systems Modeling of Acute Illness 
(CRISMA) Center, University of Pittsburgh, Pittsburgh, PA. 3Department of 
Emergency Medicine, University of Pittsburgh, Pittsburgh, PA.
Published: 22 May 2012
References
1. Light RW, Girard WM, Jenkinson SG, George RB: Parapneumonic eff usions. 
Am J Med 1980, 69:507-512.
2. Ahmed AE, Yacoub TE: Empyema thoracis. Clin Med Insights Circ Respir Pulm 
Med 2010, 4:1-8.
3. Davies CW, Kearney SE, Gleeson FV, Davies RJ: Predictors of outcome and 
long-term survival in patients with pleural infection. Am J Respir Crit Care 
Med 1999, 160:1682-1687.
4. Farjah F, Symons RG, Krishnadasan B, Wood DE, Flum DR: Management of 
pleural space infections: a population-based analysis. J Thorac Cardiovasc 
Surg 2007, 133:346-351.
5. Kroegel C, Antony VB: Immunobiology of pleural infl ammation: potential 
implications for pathogenesis, diagnosis and therapy. Eur Respir J 1997, 
10:2411-2418.
6. Davies CW, Gleeson FV, Davies RJ: BTS guidelines for the management of 
pleural infection. Thorax 2003, 58(Suppl 2):ii18-28.
7. Misthos P, Sepsas E, Konstantinou M,Athanassiadi K, Skottis I, Lioulias A: Early 
use of intrapleural fi brinolytics in the management of postpneumonic 
empyema:a prospective study. Eur J Cardiothorac Surg 2005, 28:599-603.
8. Simpson G, Roomes D, Heron M: Eff ects of streptokinase and 
deoxyribonuclease on viscosity of human surgical and empyema pus. 
Chest 2000, 117:1728-1733.
9. Tokuda Y, Matsushima D, Stein GH, Miyagi S: Intrapleural fi brinolytic agents 
for empyema and complicated parapneumonic eff usions: a meta-analysis. 
Chest 2006, 129:783-790.
10. Heff ner JE. Multicenter trials of treatment for empyema — after all these 
years. N Engl J Med 2005, 352:926-8.
doi:10.1186/cc11337
Cite this article as: Safi yeh M, Huang D: New strategies to manage 
complicated pleural eff usions. Critical Care 2012, 16:312.
Safi yeh and Huang Critical Care 2012, 16:312 
http://ccforum.com/content/16/3/312
Page 2 of 2
